US › Healthcare

DiaMedica Therapeutics Inc (DMAC)

US · Healthcare · Biotechnology

$6.85+3.32%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-10.1M

EPS

$-0.19

EPS estimate

$-0.19

EPS came in at -0.19 against a street estimate of -0.19 — a beat of 0.0%.

Key statistics

Market cap

$352.1M

Forward P/E

0.0

P/B

9.21

Book value

$0.71

EPS (TTM)

$-0.72

52-week high

$10.42

52-week low

$5.25

50-day MA

$6.84

200-day MA

$7.18

Beta

0.97

Analyst view

Analysts rate DiaMedica Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $15.50.

Shareholding

Insiders

27.83%

Institutions

40.91%

Largest institutional holders

Fund	Stake
Cooperman Leon G	6.40%
BlackRock Inc	3.44%
PARAGON Assoc & PARAGON Assoc II JV	1.62%
Millennium Management LLC	1.57%
Geode Capital Management, LLC	1.45%
State Street Corp	1.19%
First Manhattan Co. LLC	0.84%
Bleichroeder LP	0.71%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for DiaMedica Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.